A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 Immunoglobulin G (rCD4-IgG) in Infants and Children With Documented HIV-1 Infection

Inclusion Criteria Patients must have the following: * HIV-1 infection, or if less than 15 months old, born to mother with HIV-1 infection. * Legally qualified guardian with the ability to sign a written, informed consent form. * Willingness to abstain from all other experimental therapy for HIV-1 infection during the first 12 weeks of the study period. * Anticipated life expectancy of at least 3 months. Prior Medication: Allowed: * Prophylactic anti-Pneumocystis carinii pneumonia (PCP) or antifungal therapy. * Gamma globulin as prophylaxis for measles and varicella. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: * Past or present history of neurological abnormalities including withdrawal syndrome or seizures. * Past or present history of any serious active opportunistic infection including Pneumocystis carinii pneumonia (PCP). * Echocardiogram values \> 2 standard deviations from normal. * Hematologic, renal, or hepatic insufficiency. Concurrent Medication: Excluded: * Zidovudine (AZT). * Intravenous gamma globulin (IVIG) except as prophylaxis for measles and varicella. * Cancer chemotherapy. * Corticosteroids. * Other known immunomodulatory agents. * Other experimental therapy not specifically allowed. Patients with the following are excluded: * Hematologic, renal, or hepatic insufficiency. * Past or present history of any serious active opportunistic infection. Prior Medication: Excluded for a minimum of 3 weeks prior to study entry: * Zidovudine (AZT). * Intravenous gamma globulin (IVIG). * Cancer chemotherapy. * Immunomodulatory agents. * Acyclovir and other experimental therapy. Risk Behavior: Excluded: * Patients born to substance abusing mothers (including alcohol) during the pregnancy.